Skip To Main Content
US Patient Site

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COLUMVI® (glofitamab-gxbm) COTELLIC® (cobimetinib) ENSPRYNG™ (satralizumab-mwge) Erivedge® (vismodegib) Evrysdi® (risdiplam) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk) Itovebi™ (inavolisib) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) LUNSUMIO® (mosunetuzumab-axgb) OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq) PERJETA® (pertuzumab) PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) PiaSky™ (crovalimab-akkz) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO® (ranibizumab injection) TECENTRIQ® (atezolizumab) TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) VABYSMO® (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

ACTEMRA® (tocilizumab)‎ ALECENSA® (alectinib) Avastin® (bevacizumab) COLUMVI® (glofitamab-gxbm) COTELLIC® (cobimetinib) ENSPRYNG™ (satralizumab-mwge) Erivedge® (vismodegib) Evrysdi® (risdiplam) GAZYVA® (obinutuzumab) HEMLIBRA® (emicizumab-kxwh) Herceptin® (trastuzumab) Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk) Itovebi™ (inavolisib) KADCYLA® (ado-trastuzumab emtansine) LUCENTIS® (ranibizumab injection) LUNSUMIO® (mosunetuzumab-axgb) OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq) PERJETA® (pertuzumab) PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) PiaSky™ (crovalimab-akkz) POLIVY® (polatuzumab vedotin-piiq) Pulmozyme® (dornase alfa) Inhalation Solution Rituxan® (rituximab) for Rheumatoid Arthritis (RA) RITUXAN® (rituximab) for Oncology Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV) RITUXAN HYCELA® (rituximab/hyaluronidase human) ROZLYTREK® (entrectinib) SUSVIMO® (ranibizumab injection) TECENTRIQ® (atezolizumab) TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) VABYSMO® (faricimab-svoa) VENCLEXTA® (venetoclax tablets) XOLAIR® (omalizumab) for subcutaneous use ZELBORAF® (vemurafenib) Oncology Ophthalmology Rheumatology

The Evrysdi Co-pay Program

Genentech co-pay programs provide financial assistance to eligible commerically insured patients to help with their co-pays, co-insurance or other out-of-pocket (OOP) costs. If your patients have commercial health insurance and meet other eligibility criteria, the Evrysdi Co-pay Program may be able to help them pay for Evrysdi.

To get started, call (833) 387-9734.

Eligibility criteria and benefit limits apply. Not valid for patients whose prescriptions are reimbursed under any federal or state government programs to pay for their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.

phone

For assistance, call (877) GENENTECH/(877) 436-3683
6 a.m.–5 p.m. PT, Monday through Friday

form

To enroll in MySMA Support, complete and submit the Evrysdi Start Form